On November 23, 2004, Inyx announced it was awarded an exclusive five-year contract to produce NovaDel’s nitroglycerin lingual spray for the treatment of acute angina, the first of NovaDel’s Tier One priority products to reach the stage of new drug application (NDA) review by the FDA.
“We are pleased with our expanding, long-term relationship with NovaDel,” said Jack Kachkar, chairman and CEO of Inyx. “We look forward to NovaDel being one of our important new clients for whom we will be producing out of the Manati, Puerto Rico production complex that Inyx is acquiring from Sanofi-Aventis Group.”
The acquisition of the Manati complex, which consists of five buildings totaling about 140,000 square feet and extends over 9.5 acres, is scheduled to close on March 31, 2005.